A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma

Trial Profile

A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Elotuzumab (Primary) ; Lenalidomide (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 04 Jul 2017 Planned number of patients changed from 516 to 564.
    • 04 Jul 2017 Planned End Date changed from 1 Mar 2022 to 1 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top